DSGN Company Profile and Key Details

Q: Who are the executives of DSGN?

Ms. Dawn GiangiulioControllerDr. Elizabeth Gordon Ph.D.Senior Vice President of Regulatory AffairsDr. Jae B. Kim FACC, M.D.Chief Medical OfficerDr. Sean Jeffries Ph.D.Chief Operating OfficerDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorMs. Julie D. Burgess CPAChief Accounting OfficerMr. Pratik Shah Ph.D.Co-Founder & Executive ChairpersonDr. João Siffert M.D.Pres, Chief Executive Officer & Director

NASDAQ : DSGN

Design Therapeutics

$9.59

0.14+1.48%

Open: 3:54 PM

60.11

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Design Therapeutics, Inc. (DSGN) stock surged +1.48%, trading at $9.59 on NASDAQ, up from the previous close of $9.45. The stock opened at $9.45, fluctuating between $9.36 and $9.78 in the recent session.

Stock Snapshot

9.45

Prev. Close

546.28M

Market Cap

9.36

Day Low

-8.06

P/E Ratio

-1.19

EPS (TTM)

-1.1

Cash Flow per Share

9.45

Open

56.96M

Number of Shares

9.78

Day High

58.14%

Free Float in %

5.09

Book Value

120.04K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	9.06	9.78	9.06	9.45	218.85K
Jan 16, 2026	9.39	9.75	9.04	9.28	231.97K
Jan 15, 2026	9.78	9.91	9.01	9.36	452.34K
Jan 14, 2026	9.57	10.01	9.57	9.80	124.94K
Jan 13, 2026	9.06	9.80	8.82	9.57	162.15K
Jan 12, 2026	9.31	9.49	8.84	9.12	344.27K
Jan 09, 2026	9.29	9.89	9.29	9.39	167.12K
Jan 08, 2026	9.84	9.91	8.87	9.18	245.75K
Jan 07, 2026	9.36	10.17	9.33	9.87	251.1K
Jan 06, 2026	8.62	8.98	8.59	8.82	197.11K
Jan 05, 2026	9.07	9.07	8.23	8.69	481.71K
Jan 02, 2026	9.46	9.71	8.94	9.10	218.43K
Dec 31, 2025	9.79	9.88	9.23	9.38	794.22K
Dec 30, 2025	9.76	10.01	9.62	9.79	393.83K
Dec 29, 2025	9.53	9.82	9.46	9.79	372.38K
Dec 26, 2025	9.67	9.77	9.46	9.63	111.45K
Dec 24, 2025	9.72	10.08	9.69	9.74	136.07K
Dec 23, 2025	9.80	10.07	9.44	9.60	939.77K
Dec 22, 2025	9.73	10.11	9.65	9.96	791.32K
Dec 19, 2025	9.03	9.83	8.43	9.68	886.52K

Contact Details

Carlsbad, CA 92011

United States

https://www.designtx.com 858 293 4900

About Company

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Design Therapeutics, Inc. (NASDAQ:DSGN) closed at $9.59 USD, gaining $0.14 (1.48%) from the previous close of $9.45. The stock is currently mid-range between its 52-week high and low $2.60 and $10.31. With a market capitalization of about $546.28 million, Design Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.64). Key stats such as the average daily volume over the past year has been around 397.86 thousand shares, volume is running light vs its 52-week average. Headquartered in Carlsbad, CA, Design Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pratik Shah, the company employs approximately 56 people and listed since March 29, 2021. Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions.

Technical Performance

DSGN has shown sold momentum, gaining 3.62% over the past week and 64.63% over the past quarter, though year-to-date performance is up 0.75%. Short-term trend indicators are bearishly aligned (SMA20 -0.11%, SMA50 5.63%, SMA200 63.23%). The stock’s 14-day RSI is 52.25 (neutral), while the ATR of 0.71 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -8.3% below its high and over 263.46% above its low. Average 10-day trading volume of 255.75 thousand shares is below the 3-month average of 348.70 thousand, indicating normal recent market interest.

Valuation Metrics

Design Therapeutics, Inc. trades at a P/E ratio of -7.98, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.69 suggesting the stock is closer to book value. The P/FCF stands at -10.27, also below market averages.

Dividend & Fair Value

Design Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Design Therapeutics, Inc. generated EPS of -$1.19 over the past year. Five-year average earnings growth is -88.52%. Wall Street analysts project EPS growth of -18.76% annually over the next five years. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.35. Next year's EPS is expected at -$7.92. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $6.00. The high target offers 90.48% upside. The low target suggests -36.51% downside. The mean target is $12.75. This offers 34.92% upside. Design Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -11.76%. The prior quarter beat by 6.25%. Over the last six quarters, Apple has recorded several small beats. These include -16.0% in August 05, 2024.

Shareholding & Insider Activity

Design Therapeutics, Inc. has 56.95 million shares outstanding. The public float is 23.34 million shares, elevated short interest at 9.34% of float. This equals 3.52 million shares. The short ratio is 22.33 days. Institutional investors hold 98.45% of the float. Insiders own 35.98%. SR One Capital Fund I Aggregator LP holds 6.53 million shares, George Simeon has 6.53 million shares and Cormorant Asset Management, LP has 5.11 million shares. Over the past six months, insider transactions show net selling. They sold 217.63 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Design Therapeutics has not generated any revenue. Returns are negative, with ROA at -23.08% and ROE at -24.08%.
On valuation metrics, Design Therapeutics trades at a P/E of -7.98, P/S of 0.00 and P/B of 2.69. The current ratio is 18.71 and quick ratio is 18.71. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -47.37 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -29.98.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Design Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $78.19M (margin 0.0%). Net income was- $66.86M (EPS - $0.00).
The company ended the quarter with $281.80M in cash and short-term investments, a total debt of $2.33M, and net debt of - $18.87M. Total assets were $289.64M, with equity of $277.69M. Financials further reflected weakness, with operating cash flow of - $58.56M, free cash flow of - $58.82M, and capital expenditures of - $256.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Design Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.11%, with price expected at $9.44 by February 03, 2026, within a range of $9.02 to $9.84 3-Month Outlook: Projected fall of -13.02%, reaching $8.22 by April 16, 2026, with a range of $8.02 to $8.42. 1-Year Outlook: Projected gain of 274.71%, with price at $35.41 by January 15, 2027, within a range of $36.31 to $42.42.

Key Takeaways

Design Therapeutics, Inc. (NASDAQ:DSGN) shares are flat 0.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Design Therapeutics, Inc. trading at a premium to the broader market with a P/E of -7.98. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $17.31, suggesting 83.17% upside. Our AI forecast model points to short-term weakness (-0.11% over two weeks), a medium-term fall (-13.02% over three months), and a longer-term gain (274.71% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Design Therapeutics, Inc. (DSGN) stock price?

Design Therapeutics, Inc. (NASDAQ: DSGN) stock price is $9.59 in the last trading session. During the trading session, DSGN stock reached the peak price of $9.78 while $9.36 was the lowest point it dropped to. The percentage change in DSGN stock occurred in the recent session was 1.48% while the dollar amount for the price change in DSGN stock was $0.14.

DSGN's industry and sector of operation?

The NASDAQ listed DSGN is part of Biotechnology industry that operates in the broader Healthcare sector. Design Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of DSGN?

Ms. Dawn Giangiulio
Controller
Dr. Elizabeth Gordon Ph.D.
Senior Vice President of Regulatory Affairs
Dr. Jae B. Kim FACC, M.D.
Chief Medical Officer
Dr. Sean Jeffries Ph.D.
Chief Operating Officer
Dr. Aseem Z. Ansari Ph.D.
Co-Founder & Scientific Advisor
Ms. Julie D. Burgess CPA
Chief Accounting Officer
Mr. Pratik Shah Ph.D.
Co-Founder & Executive Chairperson
Dr. João Siffert M.D.
Pres, Chief Executive Officer & Director

How DSGN did perform over past 52-week?

DSGN's closing price is 263.46% higher than its 52-week low of $2.60 where as its distance from 52-week high of $10.31 is -8.31%.

How many employees does DSGN have?

Number of DSGN employees currently stands at 56.

Link for DSGN official website?

Official Website of DSGN is: https://www.designtx.com

How do I contact DSGN?

DSGN could be contacted at phone 858 293 4900 and can also be accessed through its website. DSGN operates from 6005 Hidden Valley Road, Carlsbad, CA 92011, United States.

How many shares of DSGN are traded daily?

DSGN stock volume for the day was 120.04K shares. The average number of DSGN shares traded daily for last 3 months was 397.86K.

What is the market cap of DSGN currently?

The market value of DSGN currently stands at $546.28M with its latest stock price at $9.59 and 56.96M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	56
Beta	1.64
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

DSGN Company Profile and Key Details

Design Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Company Overview

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics